Ivabradin and Verapamil Sr efficacy in treatment of coronary heart disease accompanied by bronchial obstructive diseases

Abstract

The aim of the research is a comparative investigation of Ivabradin vs Verapamil SR of antianginal/antiischemic activity, physical exertion tolerance and life quality of patients with coronary heart disease (CHD) accompanied by bronchial obstructive diseases. Parallel groups of patients have been examined for a 16-week period. Ivabradin (average dose — 14mg/day) or Verapamil SR (average dose — 443mg/day) were administered to ischemic patients (n=84) with postinfarction cardiosclerosis, stable angina (class l-ll) and painless myocardial ischemia. Concomitant bronchial obstructive deseases included controlled/partly controlled bronchial asthma or chronic obstructive pulmonary disease (stage II-III). Both medications have demonstrated the same antianginal/antiischemic activity and have improved physical exertion tolerance. Ivabradin was more effective for heart rate (HR) aim level and 24-hour HR control. Ivabradin advantages were more expressed by changing of NYHA class (from class II to class I) and increase of 6MWD. In conclusion Ivabradin has demonstrated its effectiveness in life quality improvement. Ivabradin and Verapamil SR did not cause complications in concomitant asthma/COPD and were good tolerated. It was determined that Ivabradin is a good Verapamil SR alternative for CHD treatment in case of bronchial obstructive concomitant diseases

Keywords

• bronchial obstructive diseases
• coronary heart diseases
• Ivabradin
• Verapamil SR